VRDN
|
$14.28
-2.19%
-2.24%
810K
|
Health Care and Social Assistan...
(0.0% 1d)
(-18.5% 1m)
(-50.8% 1y)
(0.0% 2d)
(0.0% 3d)
(-5.2% 7d)
(-45.46%
volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 896,320,900
http://www.miragen.com/
Sec
Filling
|
Patents
| 27 employees
(US) Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED). Viridian is headquartered in Boulder, Colorado , with research and development operations in Waltham, Massachusetts.
treatment
antibody
add to watch list
Paper trade
email alert is off